Chat with us, powered by LiveChat

May 2022

5 things you should know about the data in the Lhasa Carcinogenicity Database (LCDB)

With technical input from Andrew Thresher. Would your toxicology assessments benefit from free access to long-term carcinogenicity study data? The Lhasa Carcinogenicity Database (LCDB) is a widely used, free resource of long-term carcinogenicity study data. In this article we explore 5 things you should know about the data in the LCDB. 1. The Lhasa Carcinogenicity […]

5 things you should know about the data in the Lhasa Carcinogenicity Database (LCDB) Read More »

Is expert review an essential step when assessing mutagenic potential of drug impurities?

When assessing the mutagenic potential of drug impurities in silico, the ICH M7 guideline states that two complementary (Q)SAR prediction methodologies should be applied. A provision for the application of ‘expert knowledge’ is also mentioned within the guideline. However, as (Q)SAR models continue to be updated and their predictive performance and structural coverage improves, this raises

Is expert review an essential step when assessing mutagenic potential of drug impurities? Read More »